QSAM Biosciences, Inc. announced the activation of its first clinical trial site and the initiation of enrollment of patients into its Phase I clinical trial evaluating CycloSam® for multiple types of bone cancer that either originated in or has metastasized to the bone.
[QSAM Biosciences, Inc.]
7992332
{7992332:BBBBBBBB}
apa
50
1
169754
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
